New combo therapy aims to shrink rectal tumors before surgery

NCT ID NCT06770270

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a new immunotherapy drug called pucotenlimab to the standard pre-surgery treatment (chemotherapy and radiation) works better for people with locally advanced rectal cancer. The goal is to see if this combination helps more patients achieve a complete response, meaning no detectable cancer cells remain, before they undergo surgery. Researchers will enroll 68 adults to assess the safety and effectiveness of this approach.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECTAL CANCER